A pooled analysis of mortality in patients with COPD receiving triple therapy versus dual bronchodilation

Marc Miravitlles; P M Calverley; Katia M.C. Verhamme; M. Dreher; Valentina  Bayer; Asparuh Gardev; Alberto  de la Hoz; Jadwiga A Wedzicha; David Price

A pooled analysis of mortality in patients with COPD receiving triple therapy versus dual bronchodilation

Marc Miravitlles^* (Corresponding Author), P M Calverley, Katia M.C. Verhamme, M. Dreher, Valentina Bayer, Asparuh Gardev, Alberto de la Hoz, Jadwiga A Wedzicha, David Price

^*Corresponding author for this work

Research output: Contribution to conference › Abstract › peer-review

7 Downloads (Pure)

Abstract

A possible mortality benefit of long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA)/inhaled corticosteroid (ICS) versus LAMA+LABA combination treatment is reported in patients with highly symptomatic chronic obstructive pulmonary disease (COPD) with a history of exacerbations (≥1 moderate/severe exacerbation in previous year). We compared the time to all-cause mortality with LAMA+LABA+ICS versus LAMA+LABA in patients with moderate-to- severe COPD and predominantly lower exacerbation risk.

Original language	English
Number of pages	1
Publication status	Accepted/In press - 13 Sept 2021
Event	Eastern Pulmonary Conference 2021 - Palm Beach, UNITED STATES Duration: 30 Sept 2021 → 3 Oct 2021 https://easternpulmonaryconference.org

Conference

Conference	Eastern Pulmonary Conference 2021
Country/Territory	UNITED STATES
City	Palm Beach
Period	30/09/21 → 3/10/21
Internet address	https://easternpulmonaryconference.org

Access to Document

Miravitlles_etal_a_pooled_analysis_AAMAccepted author manuscript, 73.9 KBLicence: Unspecified

Cite this

@conference{f47e1e46e7984165ad73c6535e201740,

title = "A pooled analysis of mortality in patients with COPD receiving triple therapy versus dual bronchodilation",

abstract = "A possible mortality benefit of long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA)/inhaled corticosteroid (ICS) versus LAMA+LABA combination treatment is reported in patients with highly symptomatic chronic obstructive pulmonary disease (COPD) with a history of exacerbations (≥1 moderate/severe exacerbation in previous year). We compared the time to all-cause mortality with LAMA+LABA+ICS versus LAMA+LABA in patients with moderate-to- severe COPD and predominantly lower exacerbation risk.",

author = "Marc Miravitlles and Calverley, {P M} and Verhamme, {Katia M.C.} and M. Dreher and Valentina Bayer and Asparuh Gardev and {de la Hoz}, Alberto and Wedzicha, {Jadwiga A} and David Price",

year = "2021",

month = sep,

day = "13",

language = "English",

note = "Eastern Pulmonary Conference 2021 ; Conference date: 30-09-2021 Through 03-10-2021",

url = "https://easternpulmonaryconference.org",

}

TY - CONF

T1 - A pooled analysis of mortality in patients with COPD receiving triple therapy versus dual bronchodilation

AU - Miravitlles, Marc

AU - Calverley, P M

AU - Verhamme, Katia M.C.

AU - Dreher, M.

AU - Bayer, Valentina

AU - Gardev, Asparuh

AU - de la Hoz, Alberto

AU - Wedzicha, Jadwiga A

AU - Price, David

PY - 2021/9/13

Y1 - 2021/9/13

N2 - A possible mortality benefit of long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA)/inhaled corticosteroid (ICS) versus LAMA+LABA combination treatment is reported in patients with highly symptomatic chronic obstructive pulmonary disease (COPD) with a history of exacerbations (≥1 moderate/severe exacerbation in previous year). We compared the time to all-cause mortality with LAMA+LABA+ICS versus LAMA+LABA in patients with moderate-to- severe COPD and predominantly lower exacerbation risk.

AB - A possible mortality benefit of long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA)/inhaled corticosteroid (ICS) versus LAMA+LABA combination treatment is reported in patients with highly symptomatic chronic obstructive pulmonary disease (COPD) with a history of exacerbations (≥1 moderate/severe exacerbation in previous year). We compared the time to all-cause mortality with LAMA+LABA+ICS versus LAMA+LABA in patients with moderate-to- severe COPD and predominantly lower exacerbation risk.

M3 - Abstract

T2 - Eastern Pulmonary Conference 2021

Y2 - 30 September 2021 through 3 October 2021

ER -

A pooled analysis of mortality in patients with COPD receiving triple therapy versus dual bronchodilation

Abstract

Conference

Access to Document

Fingerprint

Cite this